Platelet-derived growth factor acts as a chemoattractant of smooth muscle cells in vitro. It’s in vivo, functions are undefined. Infusion of platelet-derived growth factor in rats with carotid injury, showed marginal increase in smooth muscle cell proliferation.

Platelet-derived growth factors are also been tested as a treatment for Parkinson’s disease. There is a new hope for patients with Parkinson’s disease, as the study conducted showed promising results when tested on rodents. 

Parkinson’s disease is the most common neurodegenerative disorder which takes a toll on the older population. The disease is characterized by damage of neurons or brain cells from the mid-brain. This leads to hampering of dopamine release which is responsible for control of voluntary movements. 

A group of investigators from NeuroNova AB, Department of Neuroscience, Karolinska Institutet, Sweden, Motac Neuroscience Ltd., Manchester and The Parkinson’s Institute, USA have investigated on the changes in behaviour, tissue recovery and biochemical changes in experiment models of Parkinson’s disease in rodents. These rodents were subjected to platelet-derived growth factor infusion and were observed for its effects.

Anders Haegerstrand, MD, PhD, NeuroNova AB, Sweden, mentioned about the restoration of striatal dopamine transporter binding sites and nigral tyrosine hydroxylase expression was observed after two week treatment of the animal models with nigrostriatal injury with platelet-derived growth factor. The effect of platelet-derived growth factor in rodents shows a positive effect on and proves to be a clinical candidate for treatment of Parkinson’s disease. Further clinical trials with platelet-derived growth factors, will unravel the benefits in humans with Parkinson’s disease.